The following excerpt is from the company's SEC filing.
, Vol. 21, Issue 4, April 2022, pp: 1647-1650.
peer-reviewed publication reports on a double-blinded placebo-controlled study randomizing patients to one of three treatment groups:
JW-100 (a novel topical formulation containing CBD plus aspartame), CBD only, or placebo topical formulations. The Investigator’s
Static Global Assessment (ISGA) score was used to document any changes in atopic dermatitis resulting from the applied interventions
at 14 days.
patients completed the trial and were included in the final analysis. The JW-100 cohorts demonstrated statistically significant ISGA
score reduction (p = 0.042). 50% of patients in the JW-100 group achieved ISGA score of clear or almost clear (0 or 1) with at least
a 2-grade improvement from baseline after treatment (p = 0.028). Only 20% and 15% of patients in the CBD only and placebo groups reported
ISGA score of clear or almost clear (0 or 1). JW-100, was demonstrated to produce statistically significant improvements in atopic dermatitis
following 14 days of topical application.
publication is authored by an international group of leading dermatology researchers and clinicians who conducted the studies. The studies
were coordinated by Dr. Andy Goren, Chief Medical Officer, Applied Biology Inc. (Irvine, CA). In coordination with Dr. Goren, Jupiter
has commenced a drug development program of JW-100 for the treatment of atopic dermatitis. A pre-IND meeting to discuss our development
plan was conducted with the US Federal Drug Administration at the end of 2021.
Glynn Wilson, Chief Scientific Officer of Jupiter Wellness commented, “Peer-reviewed publication of data from controlled clinical
trials conducted by leading clinicians is central to our overall strategy of developing novel medicinal products that have demonstrated
safety and efficacy and ultimately receive regulatory approval.”
John, CEO of Jupiter Wellness added, “We are excited by these initial results and the potential for JW-100 to provide a solution
superior to existing prescription drugs. The early clinical data shows JW-100’s potential to disrupt the billion-dollar market
for the treatment of eczema.”
is a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products. The
Company’s clinical pipeline of prescription CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes
cold sores, and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skincare products including
its flagship CaniSun™ sunscreen and other wellness brands sold through its robust distribution platform.
additional information, please visit
. The Company’s public filings can be found at
To the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the “Company”)
contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 and the information
that are based upon beliefs of, and information currently available to, the company’s management as well as estimates and assumptions
made by the company’s management. These statements can be identified by the fact that they do not relate strictly to historic or
current facts. When used in this presentation the words “estimate,” “expect,” intend,” believe,”
plan,” “anticipate,” “projected” and other words or the negative of these terms and similar expressions
as they relate to the company or the company’s management identify forward-looking statements. Such statements reflect the current
view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to
the company’s industry, its operations and results of operations and any businesses that may be acquired by the company. Should
one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly
from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations reflected
in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements. Except as
required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking
statements to conform these statements to actual results.
& Public Relations Contact Info
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Jupiter Wellness makes a similar move, sign up!
Other recent filings from the company include the following:
Jupiter: Srm Entertainment Announces Licensing Agreement With - Aug. 17, 2022
Jupiter Wellness Reports Second Quarter 2022 Financial Results And Operational Highlights - Aug. 16, 2022
Jupiter: Agreement To Forfeit Incentive Stock Options This Incentive Stock Option Forfeiture Agreement - July 29, 2022
CSO of Jupiter Wellness just disposed of 14,124 shares - July 27, 2022
Jupiter Wellness's CEO just disposed of 18,832 shares - July 27, 2022